Autonomix Medical announced completion of the final design review for its proprietary sensing catheter. The milestone moves the Texas-based company closer to initiating human clinical trials in the US. Earlier animal model testing showed the device could detect nerve signals in real time. The catheter is the first intravascular device designed to identify and differentiate nerve signals from within blood vessels. It features a proprietary microchip-based sensing antenna array. The platform enables physicians to detect nerve activity, guide energy delivery, optimise ablation patterns, and confirm treatment success instantly. Potential applications include cardiology, resistant hypertension, interventional pain management, and pulmonary and gastrointestinal disorders. Autonomix plans to seek FDA investigational device exemption for use in treating pancreatic cancer pain. CEO Brad Houser said the technology could transform neuromodulation by mapping nerve activity directly at the source. He described the device as a paradigm shift in therapeutic electrophysiology with potential to improve safety and effectiveness. The company aims to advance towards a De Novo FDA submission following its planned clinical trial.